10.6084/m9.figshare.7587365.v1 Bixia Tang Bixia Tang Xieqiao Yan Xieqiao Yan Xinan Sheng Xinan Sheng Lu Si Lu Si Chuanliang Cui Chuanliang Cui Yan Kong Yan Kong Lili Mao Lili Mao Bin Lian Bin Lian Xue Bai Xue Bai Xuan Wang Xuan Wang Siming Li Siming Li Li Zhou Li Zhou Jiayi Yu Jiayi Yu Jie Dai Jie Dai Kai Wang Kai Wang Jinwei Hu Jinwei Hu Lihou Dong Lihou Dong Haifeng Song Haifeng Song Hai Wu Hai Wu Hui Feng Hui Feng Sheng Yao Sheng Yao Zhihong Chi Zhihong Chi Jun Guo Jun Guo Additional file 1: of Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients Springer Nature 2019 PD-1 Monoclonal antibody JS001 Melanoma Urothelial cancer Renal cell carcinoma 2019-01-14 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Safety_and_clinical_activity_with_an_anti-PD-1_antibody_JS001_in_advanced_melanoma_or_urologic_cancer_patients/7587365 Figure S1. Phase I study schema of JS001 in advanced melanoma, renal cell carcinoma, and urothelial carcinoma. Figure S2. The PK profiles of JS001 in humans. Figure S3. The percentage of activated CD8+ T cell population during JS001 treatment. Figure S4. Correlation of tumor mutational burden (TMB) with clinical efficacy. Table S1. Treatment-related serious adverse events (SAE). Table S2. Grade 3 and above treatment-related adverse events (TRAE) in each cohort. Table S3. PD-1 receptor occupancy (RO) by JS001 in three dose cohorts. Table S4. Subgroup analysis of correlation with clinical efficacy. Table S5. Tumor mutational burden measurement and correlation with clinical response. (DOCX 575 kb)